Levetiracetam in brain ischemia: Clinical implications in neuroprotection and prevention of post-stroke epilepsy

Brain and Development

Volumn 33, Issue 4, 2011, Pages 289-293

  Belcastro, Vincenzo ^a   Pierguidi, Laura ^a   Tambasco, Nicola ^b  

^a SANT ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Brain ischemia; Epileptogenesis; Levetiracetam; Neuroprotection; Post stroke seizures

Indexed keywords

ETIRACETAM;

BRAIN ISCHEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTOGENESIS; HUMAN; NEUROPROTECTION; SHORT SURVEY; STROKE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICONVULSANTS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; NEUROPROTECTIVE AGENTS; PIRACETAM; STROKE;

EID: 79952316760     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2010.06.008     Document Type: Short Survey

References (50)

1. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43:707-724.
2. Arroyo S., Crawford P. Safety profile of levetiracetam. Epileptic Disord 2003, 5:S57-S63.
3. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408. Levetiracetam Monotherapy Study Group.
4. Abou-Khalil B., Schaich L. Long-term efficacy of levetiracetam for partial seizure. Seizure 2005, 14:577-585.
5. Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 2005, 46:154-160.
6. Zesiewicz T.A., Sullivan K.L., Maldonado J.L., Tatum W.O., Hauser R.A. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2005, 20:1205-1209.
7. Striano P., Manganelli F., Boccella P., Perretti A., Striano S. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005, 20:1610-1614.
8. Sullivan K.L., Hauser R.A., Louis E.D., Chari G., Zesiewicz T.A. Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005, 11:468-471.
9. D'Amelio M., Callari G., Gammino M., et al. Levetiracetam in the treatment of vascular corea: a case report. Eur J Clin Pharmacol 2005, 60:835-836.
10. Post R.M., Altshuler L.L., Frye M.A., et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005, 66:370-374.
11. Calabresi P., Cupini M.L., Centonze D., Pisani F., Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy of brain ischemia. Ann Neurol 2003, 53:693-702.
12. Ryvlin P., Montavont A., Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006, 67:S3-S9.
13. Klitgaard H., Pitkanen A. Antiepiletogenesis, neuroprotection and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003, 5:S9-S16.
14. Marini H., Costa C., Passaniti M., et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sci 2004, 74:1253-1264.
15. Hanon E., Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001, 10:287-293.
16. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001, 306:5-8.
17. Angehagen M., Margineau D.G., Ben-Menachem E., Ronnback L., Hansson E., Klitgaard H. Levetiracetam reduces caffeine-induced Ca transient and epileptiform potentials in hippocampal neurons. Neuroreport 2003, 14:471-475.
18. Pisani A., Bonsi P., Martella G., et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45:719-728.
19. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
20. 2+ currents. Seizure 2001, 10:279-286.
21. Madeja M., Margineau D.G., Gorji A., et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action. Neuropharmacology 2003, 45:661-671.
22. Green A.R., Hainsworth A.H., Jackson D.M. GABA potentiation: a logical pharmacological approach for the treatment of acute ischemic stroke. Neuropharmacology 2000, 39:1438-1494.
23. Margineau D.G., Klitgaard H. Levtiracetam has not significant γ-aminobutyric acid-related effect on pair-pulse interaction in the dentate gyrus of rats. Eur J Pharmacol 2003, 466:255-261.
24. Loscher W., Honak D., Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 1996, 735:208-216.
25. Poulain P., Margineau D.G. Levetiracetam opposes the action of GABA-A antagonists in hypothalamic neurones. Neuropharmacology 2002, 42:346-352.
26. Bouwman B.M., Van Rijn C.M. Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 2004, 13:591-594.
27. Calabresi P., Centonze D., Bernardi G. Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology 2000, 55:1249-1255.
28. Noyer M., Gillard M., Matagne A., Henichart J.P., Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995, 286:137-146.
29. Stahl S.M. Psycopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry 2004, 65:1162-1163.
30. Bajjalieh S.M., Frantz G.D., Weimann J.M., McConnell S.K., Scheller R.H. Differential expression of synaptic vesicle protein 2 (SV2) isoform. J Neurosci 1994, 14:5223-5235.
31. Lamberg N., Gillard M., Vertongen P., Fuks B., Chatelain P. Characterization of 3H-ucb30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Eur J Pharmacol 2005, 520:70-76.
32. Bajjalieh S.M., Peterson K., Linial M., Scheller R.H. Brain contain two forms of synaptic vesicle protein 2. Proc Natl Acad Sci 1993, 90:2150-2154.
33. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2003, 26:9861-9866.
34. Eya S., Yagen B., Sobol E., Altschuler Y., Shmuel M., Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004, 45:737-744.
35. De Rujiter A., Van Gennip A., Caron H.N., Kemp S., Van Kuilenburg A.B. Histone deacetylases: characterization of the classical HADC family. Biochem J 2003, 370:737-749.
36. Menon B., Shorvon S.D. Ischaemic stroke in adults and epilepsy. Epilepsy Res 2009, 87:1-11.
37. Brodie M.J., Elder A.T., Kwan P. Epilepsy in later life. Lancet Neurol 2009, 8:1019-1030.
38. Gupta S.R., Naheedy M.H., Elias D., Rubino F.A. Postinfarction seizures: a clinical study. Stroke 1988, 19:1477-1481.
39. Heiss W.D., Huber M., Fink G.R., Herholz K., Pietrzyk U., Wagner R., et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992, 12:193-203.
40. Reith J., Jorgensen H.S., Nakayama H., Raaschou H.O., Olsen T.S. Seizures in acute stroke: predictors and prognostic significance. The Copenhagen stroke study. Stroke 1997, 28:1585-1589.
41. Luhmann H.J., Mudrick-Donnon L.A., Mittmann T., Heinemann U. Ischemia-induced long-term hyperexcitability in rat neocortex. Eur J Neurosci 1995, 7:180-191.
42. Buchkremer-Ratzmann I., August M., Hagemann G., Witte O.W. Epileptiform discharges to extracellular stimuli in rat neocortical slices after photothrombotic infarction. J Neurol Sci 1998, 156:133-137.
43. Loscher W., Honack D., Runfeldt C. Antiepileptogenic effects of the novel anticonvulsivant levetiracetam (ucbL059) in the kindling model of temporal lobe epilepsy. Pharmacol Exp Ther 1998, 284:474-479.
44. Ji-qun C., Ishihara K., Nagayama T., Serikawa T., Sasa M. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Epilepsia 2005, 46:1362-1370.
45. Meador K.J., Gevins A., Loring D.W., et al. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology 2007, 69:2076-2084.
46. Belcastro V., Costa C., Galletti F., et al. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 2007, 14:1176-1178.
47. Belcastro V., Costa C., Galletti F., et al. Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Epilepsy Res 2008, 82:223-226.
48. Kutlu G., Gomceli Y.B., Unal Y., Inan L.E. Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav 2008, 13:542-544.
49. Leppik I.E. Epilepsy in the elderly. Epilepsia 2006, 47:65-70.
50. Hirsch L.J., Arif H., Buchsbaum R., et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007, 48:1351-1359.